|

Endocrine therapy Clinical Trials

8 actively recruiting trials across 2 locations

Also known as: hormone therapy

Pipeline

Phase 2: 5Phase 3: 1Phase 1/2: 1

Top Sponsors

Xijing Hospital1
The First Affiliated Hospital with Nanjing Medical University1
SciClone Pharmaceuticals1
Region Örebro County1
Puma Biotechnology, Inc.1

Indications

Breast Cancer8
Cancer8
Metastatic Breast Cancer2
Advanced Breast Cancer2
HR+ Metastatic Breast Cancer1

Other6 trials

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Phase 2

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Phase 3

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Phase 2

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2

Birmingham, Alabama1 trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Alabama Oncology

Phase 2

Tampa, Florida1 trial

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Moffitt Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.